Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis [0.03%]
venetoclax联合奥比乌马布单抗治疗初治且适合移植的慢性淋巴细胞白血病患者的加拿大成本效用分析
Gijs van de Wetering,Carolyn Owen,Versha Banerji et al.
Gijs van de Wetering et al.
Background/objective: Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disorder diagnosed in Canada and is associated with a significant economic burden. This study evaluates the cost effectivenes...
Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment [0.03%]
帕金森综合症的低成本模型构建及早期医疗技术评估
Tobias Sydendal Grand,Shijie Ren,Praveen Thokala et al.
Tobias Sydendal Grand et al.
Background and objectives: Multiple system atrophy is a neurodegenerative and rapidly progressing disease. Although symptoms often overlap, diagnostic criteria define two motor phenotypes: cerebellar and Parkinsonian. Lit...
The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland [0.03%]
澳大利亚、英格兰、加拿大和苏格兰关于多发性硬化症修正治疗的成本效益评估的连贯性和可转移性分析
Xiang Wang,Feili Zhao,David Newby et al.
Xiang Wang et al.
Objective: Our study examines the consistency and transferability of cost-effectiveness values, specifically the incremental cost-effectiveness ratio (ICER), focusing on several disease-modifying therapies (DMTs) for rela...
An Introduction to Costing and the Types of Costs Used within Health Economic Studies [0.03%]
卫生经济学研究中的成本核算及各类成本介绍
Hugo C Turner,Juan Carlos Rivillas-Garcia,Shankar Prinja et al.
Hugo C Turner et al.
The number of published health economic analyses, especially economic evaluations, has rapidly expanded globally since the 1990s, and costs are an essential component of such studies. Cost is a general term that refers to the value of the r...
Carer Health-Related Quality of Life: A Review of Modelling Considerations in National Institute for Health and Care Excellence Technology Appraisals (2000-2023) [0.03%]
照料者健康相关生活质量：英国国家卫生与护理卓越研究所技术评估（2000-2023）中建模考虑因素的回顾分析
Charlotte Ahmadu,Elise Evers,Johanna Lister et al.
Charlotte Ahmadu et al.
Objectives: Carer health-related quality of life (HRQoL) is increasingly used to support health technology assessments conducted by the National Institute for Health and Care Excellence (NICE). Modelling approaches and un...
The Economic and Clinical Impact of Recurring Automated Red Blood Cell Exchange to Manage Sickle Cell Disease in the UK [0.03%]
英国反复自动红血细胞交换对镰状细胞性疾病经济和临床影响的研究
Sarah M Medland,Jamie Bainbridge,Matthew Cawson et al.
Sarah M Medland et al.
Background/objective: Sickle cell disease (SCD) is a group of inherited health conditions affecting 7.74 million people worldwide. Regular automated red blood cell exchange (aRBCX) transfusions have been shown to improve ...
Estimating the Value of Adding 30 Days to the 180-Day Market Exclusivity of the First-to-File Generic Drug Manufacturer [0.03%]
对首家首仿药企市场独占期增加30天进行估价
Aylin Sertkaya,Zeid El-Kilani,Sean Klein et al.
Aylin Sertkaya et al.
Objectives: As an additional incentive to bringing more generic drugs to more markets sooner, our aim was to estimate the value of adding 30 days to the 180 days of market exclusivity currently granted to a qualifying fir...
A Budget Impact Model of Treatment of Primary Immune Deficiency with Immune Globulin Subcutaneous (Human), 20% (IgPro20) (Hizentra) [0.03%]
primary immune deficiency使用免疫球蛋白亚cutaneous（人类），20％（IgPro20）（Hizentra）的治疗预算影响模型
Rajiv Mallick,Rashad Carlton
Rajiv Mallick
Background: Primary immune deficiency (PID) comprises over 400 inborn errors of immunity. Immune globulin replacement therapy (IGRT) is the standard of care for many PID subtypes. Intravenous immunoglobulin (IVIG) is the ...
Cost Effectiveness of Recombinant Zoster Vaccine and Live-Attenuated Vaccine Against Herpes Zoster for Adults Aged 50 and Over in China [0.03%]
中国50岁以上成人带状疱疹减毒活疫苗和重组亚单位疫苗的有效性及成本效益分析研究
Lulu Liu,Qilin Zhang,Yamin Shu et al.
Lulu Liu et al.
Objective: Two vaccines against herpes zoster (HZ) are currently authorized for use in China: the adjuvanted recombinant zoster vaccine (RZV) and live-attenuated Zoster Vaccine Live (ZVL). The significant disparities in p...
Ellen M Howard,Marc Massetti,Gin Nie Chua et al.
Ellen M Howard et al.
Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic t...